cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Muhammad Sulaiman Zubair
Contact Email
sulaiman_zubair80@yahoo.co.id
Phone
+6285242083654
Journal Mail Official
jurnalgalenika.farmasiuntad@gmail.com
Editorial Address
Jurusan Farmasi Fakultas Matematika dan Ilmu Pengetahuan Alam, Universitas Tadulako
Location
Kota palu,
Sulawesi tengah
INDONESIA
Jurnal Farmasi Galenika (Galenika Journal of Pharmacy)
Published by Universitas Tadulako
ISSN : 24427284     EISSN : 24428744     DOI : https://doi.org/10.22487/j24428744
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Medicine & Pharmacology
Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (E-ISSN: 2442-8744) (p-ISSN: 2442-7284), is an open access journal (print and e-journal) focusing on the scientific works in the field of Pharmacy and Pharmaceutical Science. The articles of this journal are published every six months, that is March and October (2 issues per year). This journal is developed by Department of Pharmacy, Faculty of Mathematics and Natural Science, Tadulako University and has been identified in Crossref with the DOI Number : 10.22487/j24428744. Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) has been accredited by Kemenristekdikti as Sinta 3 starting from Volume 5 No 1 2019.
Arjuna Subject : Pharmacology, Toxicology and Pharmaceutics - Ilmu Farmasi
Articles 253 Documents
 22   23   24   25   26 
Nanospanlastics For Transdermal and Topical Drug Delivery: Formulation, Characterization, and Therapeutic Applications: Nanospanlastik untuk Penghantaran Obat Transdermal dan Topikal: Formulasi, Karakterisasi, dan Aplikasi Terapeutik Rahmadiani, Fitria; Hendradi, Esti; Purwanti, Tutiek
Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal) Vol. 12 No. 1 (2026): (March 2026)
Publisher : Universitas Tadulako

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22487/j24428744.2026.v12.i1.17933

Abstract

Nanospanlastic is an elastic nanovesicular drug delivery system developed to enhance skin penetration, retention, and therapeutic efficacy in topical and transdermal applications. However, variations in formulation methods, characterization parameters, and evaluation approaches across studies have limited the standardization of its performance. This review was conducted systematically in accordance with the PRISMA guidelines. A comprehensive literature search was performed using international electronic databases, including ScienceDirect, Springer, PubMed, SAGE, and Taylor & Francis online, covering publications from 2015 to 2025. The keywords used were "nanospanlastic,” “spanlastic,” “nanovesicles,” “transdermal,” “topical,” “characterization,” and “application.” Articles were screened based on predefined inclusion and exclusion criteria, and 32 eligible studies were selected for qualitative meta-synthesis analysis. This article presents a cross-study comparative analysis focusing on formulation factors, physicochemical characteristics, deformability, stability, and dermatological applications. The synthesis results indicate that surfactant–edge activator composition, manufacturing methods, and component ratios significantly influence particle size, polydispersity index (PDI), entrapment efficiency, and deformability index, which, in turn, determine skin penetration and retention performance. Although nanospanlastic demonstrates improved permeation and promising pharmacological effects, challenges remain regarding long-term stability, chronic safety, and scalability for GMP-based industrial production. This review highlights critical research gaps and proposes future development directions, including formulation optimization, harmonization of characterization methods, and broader clinical validation. Therefore, nanospanlastic represents a promising innovative platform for dermatological drug delivery but requires further systematic and translational development
The Pharmacokinetics of Single-Inhaler Triple Therapy in COPD: A Systematic Reviews Arenawati, Sang Ayu Made; Dharmanta, I Nyoman Dwika; Made Ary Sarasmita; Eka Indra Setyawan; Luh Putu Mirah Kusuma Dewi
Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal) Vol. 12 No. 1 (2026): (March 2026)
Publisher : Universitas Tadulako

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22487/j24428744.2026.v12.i1.17960

Abstract

Background: The integration of inhaled corticosteroids, long-acting -agonists, and long-acting muscarinic antagonists into a fixed-dose Single Inhaler Triple Therapy (SITT) represents a pivotal strategy for managing chronic obstructive pulmonary disease (COPD) in patients with persistent symptomatology or frequent exacerbations. Despite the proven clinical efficacy of SITT, data regarding its pharmacokinetic properties across both healthy volunteers and the COPD population appear disjointed, warranting a comprehensive synthesis. Methods: We executed a systematic review following the PRISMA 2020 framework. A rigorous search of electronic databases was undertaken to retrieve clinical and population pharmacokinetic trials examining SITT. Articles were screened against specific inclusion criteria, and methodological quality was scrutinised using standard risk-of-bias instruments. Data synthesis was performed narratively, prioritizing essential pharmacokinetic indicators. Results: The review consolidated data on key metrics, specifically peak plasma concentrations, total systemic exposure, and time to peak. The analysis revealed that systemic bioavailability of the triple combination components is bioequivalent to that of their respective mono- or dual-therapy formulations. Furthermore, no significant drug accumulation was detected following multiple doses. Variations in pharmacokinetic behavior were predominantly linked to patient demographics, disease severity, and inhaler handling proficiency. Conclusion: SITT exhibits a consistent and predictable pharmacokinetic profile characterized by low systemic exposure in both healthy individuals and patients with COPD. These insights reinforce the pharmacological stability and therapeutic viability of single-inhaler regimens in clinical practice.
Nanotechnology-Based Formulations of Curcuma xanthorrhiza for Modern Herbal Therapy: A Narrative Literature Review: Formulasi Berbasis Nanoteknologi Curcuma xanthorrhiza Roxb. sebagai Terapi Herbal Modern: Tinjauan Literatur Naratif Fitriani, Hannie; Luthfiansyah Azhar, Hanif; Syukri, Yandi; Pramundita Ramadani, Arba
Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal) Vol. 12 No. 1 (2026): (March 2026)
Publisher : Universitas Tadulako

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22487/j24428744.2026.v12.i1.17972

Abstract

Background: Curcuma xanthorrhiza Roxb. (temulawak) is an Indonesian medicinal plant with documented antibacterial, anti-inflammatory, antioxidant, hepatoprotective, and anticancer activities, yet its major active compounds, curcuminoids and xanthorrhizol, suffer from poor aqueous solubility, low stability, and very limited oral bioavailability. Objectives: This study aims to review nanotechnology-based formulation strategies developed to overcome the biopharmaceutical limitations of C. xanthorrhiza and to optimise its potential as a modern herbal therapy. Methods: A narrative literature review was conducted using national and international articles published mainly between 2015 and 2025 that were retrieved from PubMed, ScienceDirect, and Google Scholar with keywords related to Curcuma xanthorrhiza, nanoformulation, and drug delivery systems; data were qualitatively summarised according to type of nanoformulation, physicochemical characteristics, and in vitro or in vivo biological activities. Results: Various nanotechnology-based delivery systems were identified, including nanosuspensions, nanoemulsions, Solid Lipid Nanoparticles (SLN), Self-Nanoemulsifying Drug Delivery Systems (SNEDDS), Solid-SNEDDS, nanogels, polymeric nanoparticles, and green-synthesised metallic nanoparticles; these formulations consistently reduced particle size to the nanometre range, improved solubility and chemical stability, increased entrapment efficiency, and enhanced pharmacological effects such as anti-inflammatory, antioxidant, antimicrobial, and anticancer activities compared with conventional extracts. Conclusions: Nanotechnology-based formulations of Curcuma xanthorrhiza represent a promising strategy to improve the efficacy, safety, and practicality of temulawak as a modern herbal medicine, and further well-designed preclinical and clinical studies are required to confirm their therapeutic advantages.

Page 26 of 26 | Total Record : 253

 22   23   24   25   26 

Filter by Year

2015 2026


Reset
Filter By Issues
All Issue Vol. 12 No. 1 (2026): (March 2026) Vol. 11 No. 2 (2025): October 2025 Vol. 11 No. 1 (2025): (March 2025) Vol. 10 No. 2 (2024): (October 2024) Vol. 10 No. 1 (2024): (March 2024) Vol. 9 No. 2 (2023): (October 2023) Vol. 9 No. 1 (2023): (March 2023) Vol. 8 No. 2 (2022): (October 2022) Vol. 8 No. 1 (2022): (March 2022) Vol. 7 No. 3 (2021): (December 2021 Vol. 7 No. 2 (2021): (October 2021) Vol. 7 No. 1 (2021): (March 2021) Vol. 6 No. 2 (2020): (October 2020) Vol. 6 No. 1 (2020): (March 2020) Vol. 5 No. 2 (2019): (October 2019) Vol. 5 No. 1 (2019): (March 2019) Vol. 4 No. 2 (2018): (October 2018) Vol. 4 No. 1 (2018): (March 2018) Vol. 3 No. 2 (2017): (October 2017) Vol. 3 No. 1 (2017): (March 2017) Vol. 2 No. 2 (2016): (October 2016) Vol. 2 No. 1 (2016): (March 2016) Vol. 1 No. 2 (2015): (October 2015) Vol. 1 No. 1 (2015): (March 2015) More Issue